ResMed ties fiscal 2027 executive stock awards to adjusted EPS and revenue goals
RMD•ResMed approved fiscal 2027 performance-based stock awards for named executives, with payouts tied equally to adjusted EPS and adjusted revenue goals over three years and a relative shareholder-return modifier.
1. Award performance measures
ResMed approved fiscal 2027 performance-based restricted stock unit awards for named executive officers on November 19, 2026. The three-year design replaces absolute and relative total stockholder return measures with equally weighted annual adjusted EPS and adjusted revenue goals, and includes a relative total stockholder return modifier of 0.75 to 1.25 measured against S&P 500 companies.
2. Payouts and vesting
Threshold, target and maximum performance yield payouts of 50%, 100% and 200%, respectively, and total awards cannot exceed 200% of target. Earned units vest after compensation committee certification following the performance period, generally subject to continued service.




